[ORGANIZATION]
tirzepatide
Featured in 25 tracked stories · first seen
Situations
Expanding therapeutic uses and regulatory concerns for GLP-1
43 clusters · 180 sources · last updated
Latest: Semaglutide study shows BMI reduction in children with obesity
Medical research continues to expand the therapeutic potential of GLP-1 receptor agonists like semaglutide and tirzepatide. While semaglutide is widely used for weight loss and diabetes, new evidence suggests it may slow
South Korea obesity and diabetes medication regulation
4 clusters · 20 sources · last updated
Latest: South Korea establishes task force to crack down on illegal obesity drug sales
In late October 2026, the South Korean Ministry of Food and Drug Safety expanded the approved indications for Mounjaro (tirzepatide). The medication is now approved for adult type 2 diabetes patients with established car
GLP-1 drugs: clinical trends, safety, and market shifts
343 clusters · 1318 sources · last updated
Latest: FDA issues warning for GLP-1 drugs over vision loss risks
The clinical and economic landscape of GLP-1 medications continues to expand. Beyond obesity, research indicates potential benefits for psychiatric, respiratory, neurodegenerative, heart, sleep apnea, and addiction healt
Eli Lilly EloraTZP and retatrutide obesity drug clinicals
4 clusters · 38 sources · last updated
Latest: Eli Lilly's retatrutide outperforms Ozempic in weight loss trial
Eli Lilly has reported results from Phase 2b clinical trials for EloraTZP, a combination therapy involving eloralinantide and tirzepatide designed to treat obesity and type 2 diabetes. Data indicates the combination tar
Brazil ANVISA expands product safety enforcement
43 clusters · 290 sources · last updated
Latest: Anvisa bans Accu-Chek Active glucose test strips on Amazon
Since May 2026, Brazil’s National Health Surveillance Agency (ANVISA) has intensified enforcement of sanitary rules for pharmaceuticals, cosmetics, and consumer goods. Early actions included suspending batches of statins
Also covered in
-
Tirzepatide discontinuation linked to psychiatric symptoms in clinical report
[HEALTH] · 6 sources ·
-
Tirzepatide may activate calorie-burning brown fat
[HEALTH] · 2 sources ·
-
Eli Lilly’s Mounjaro receives FDA approval to reduce cardiovascular risks
[HEALTH] · 2 sources ·
-
Obesity impacts effectiveness of arthritis treatments
[HEALTH] · 2 sources ·
-
London inquest links student death to weight loss drug
[HEALTH] · 5 sources ·